A Prospective, Multi-center, Open-label Study of Trospium Delivered Intravesically by TAR-302-5018 to Spinal Cord Injury Subjects With Neurogenic Detrusor Overactivity (NDO)

Trial Profile

A Prospective, Multi-center, Open-label Study of Trospium Delivered Intravesically by TAR-302-5018 to Spinal Cord Injury Subjects With Neurogenic Detrusor Overactivity (NDO)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs TAR-302-5018 (Primary)
  • Indications Detrusor instability; Overactive bladder
  • Focus Adverse reactions
  • Sponsors TARIS Biomedical
  • Most Recent Events

    • 20 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
    • 20 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
    • 02 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top